152 related articles for article (PubMed ID: 30696074)
1. Liver Kinase B1-A Potential Therapeutic Target in Hormone-Sensitive Breast Cancer in Older Women.
Syed BM; Green AR; Morgan DAL; Ellis IO; Cheung KL
Cancers (Basel); 2019 Jan; 11(2):. PubMed ID: 30696074
[No Abstract] [Full Text] [Related]
2. Biology of primary breast cancer in older women treated by surgery: with correlation with long-term clinical outcome and comparison with their younger counterparts.
Syed BM; Green AR; Paish EC; Soria D; Garibaldi J; Morgan L; Morgan DA; Ellis IO; Cheung KL
Br J Cancer; 2013 Mar; 108(5):1042-51. PubMed ID: 23462719
[TBL] [Abstract][Full Text] [Related]
3. Age-Related Biology of Early-Stage Operable Breast Cancer and Its Impact on Clinical Outcome.
Syed BM; Green AR; Rakha EA; Morgan DAL; Ellis IO; Cheung KL
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33808856
[TBL] [Abstract][Full Text] [Related]
4. Biology of Oestrogen-Receptor Positive Primary Breast Cancer in Older Women with Utilisation of Core Needle Biopsy Samples and Correlation with Clinical Outcome.
Parks RM; Albanghali M; Syed BM; Green AR; Ellis IO; Cheung KL
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726924
[TBL] [Abstract][Full Text] [Related]
5. Patterns of biomarker expression in patients treated with primary endocrine therapy - a unique insight using core needle biopsy tissue microarray.
Parks RM; Albanghali MA; Syed BM; Green AR; Ellis IO; Cheung KL
Breast Cancer Res Treat; 2021 Feb; 185(3):647-655. PubMed ID: 33226492
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome.
Syed BM; Morgan D; Setty T; Green AR; Paish EC; Ellis IO; Cheung KL
PLoS One; 2017; 12(12):e0188528. PubMed ID: 29284000
[TBL] [Abstract][Full Text] [Related]
7. Analysis of PI3K/mTOR Pathway Biomarkers and Their Prognostic Value in Women with Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.
Azim HA; Kassem L; Treilleux I; Wang Q; El Enein MA; Anis SE; Bachelot T
Transl Oncol; 2016 Apr; 9(2):114-123. PubMed ID: 27084427
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival.
Kalvala J; Parks RM; Abdi J; Green AR; Cheung KL
Adv Ther; 2023 Jun; 40(6):2820-2835. PubMed ID: 37118159
[TBL] [Abstract][Full Text] [Related]
9. Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts.
Syed BM; Green AR; Nolan CC; Morgan DA; Ellis IO; Cheung KL
PLoS One; 2014; 9(7):e100573. PubMed ID: 24999743
[TBL] [Abstract][Full Text] [Related]
10. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
12. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
[TBL] [Abstract][Full Text] [Related]
14. Double-positive in triple-negative? How significant is basal cytokeratin expression in breast cancer?
Majumder A; Jagani R; Basu A
Med J Armed Forces India; 2020 Jan; 76(1):63-70. PubMed ID: 32020971
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
16. Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance.
Habashy HO; Powe DG; Rakha EA; Ball G; Paish C; Gee J; Nicholson RI; Ellis IO
Eur J Cancer; 2008 Jul; 44(11):1541-51. PubMed ID: 18538561
[TBL] [Abstract][Full Text] [Related]
17. Invasive Lobular Carcinomas Do Not Express Basal Cytokeratin Markers CK5/6, CK14 and CK17.
Khilko N; Wang J; Wei B; Hicks DG; Tang P
Breast Cancer (Auckl); 2010 Oct; 4():49-55. PubMed ID: 21151863
[TBL] [Abstract][Full Text] [Related]
18. LKB1 expression is inhibited by estradiol-17β in MCF-7 cells.
Brown KA; McInnes KJ; Takagi K; Ono K; Hunger NI; Wang L; Sasano H; Simpson ER
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):439-43. PubMed ID: 21689749
[TBL] [Abstract][Full Text] [Related]
19. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
20. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
